Thomas Fleming, a University of Washington statistician who was a prominent skeptic about the early approval of Iressa, spent much of he meaning working out exactly how the screeningtrials were designed.
There is very high certainty from well-designed trials that colon cancer screening, combined with effective follow-up and treatment of abnormal findings, reduces risk of colon cancer death by at least 35 percent and risk of getting colon cancer by 20 percent.